Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4284
−$0.0105 · -2.39%
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Regular session
$0.4284
−$0.0105 · -2.39%
Regular session · ET · Market data may be delayed.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Day range
Current $0.4284
52-week range
Current $0.4284
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
69
Bullish
Risk
75
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Day range
Current $0.4284
52-week range
Current $0.4284
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 90K USD | — | — | — | — |
| Gross profit | −90K USD | — | — | — | — |
| Research and development | 15.89M USD | 17.73M USD | 19.49M USD | 18.97M USD | 14.42M USD |
| Selling, general, and administrative | 9.12M USD | 8.79M USD | 10.02M USD | 11.54M USD | 8.39M USD |
| Operating expenses | 25.1M USD | 26.64M USD | 29.63M USD | 30.64M USD | 22.97M USD |
| Interest income | 105K USD | 550K USD | 1.37M USD | 240K USD | 306K USD |
| Depreciation and amortization | 90K USD | 126K USD | 127K USD | 130K USD | 164K USD |
| Operating income | −25.1M USD | −26.64M USD | −29.63M USD | −30.64M USD | −22.97M USD |
| Net income | −33.56M USD | −21.76M USD | −29.77M USD | −29.03M USD | −15.89M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 1, 2025 | 1:25 | — | — |
Stock split | Mar 22, 2024 | 1:15 | — | — |
Stock split | Feb 1, 2021 | 1:6 | — | — |
Effective Dec 1, 2025
1:25
Effective Mar 22, 2024
1:15
Effective Feb 1, 2021
1:6
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
